Navigation Links
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
Date:1/23/2012

ments."

"VTX-2337 provides unique abilities compared to other TLR agonists in clinical development, most notably a robust and highly selective activation of myeloid dendritic cells and natural killer cells," said Robert Hershberg, M.D., Ph.D., President and Chief Medical Officer of VentiRx. "These preclinical efficacy findings combined with the favorable safety profile of VTX-2337 established in the recently completed Phase 1 trial support the advancement of our broad clinical development program currently underway to evaluate the safety and efficacy of VTX-2337 in combination with standard of care cancer therapies."

VentiRx has advanced VTX-2337 into clinical trials designed to evaluate the compound in multiple oncology indications in combination with a variety of anticancer agents, including chemotherapy and monoclonal antibody therapy. Clinical trials of VTX-2337 currently underway include a combination study with chemotherapy in late stage ovarian cancer and a combination trial with cetuximab in head and neck cancer patients. In addition, a trial of VTX-2337 in combination with chemotherapy in metastatic breast cancer is targeted to begin in mid-2012.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of cancer. The Company's initial focus is on developing novel small molecule product candidates targeting Toll-based product candidates for oncology and allergy. VentiRx is a privately held organization with operations in Seattle. For additional information, please visit www.ventirx.com.

 

Contact:

Robert Hershberg, M.D., Ph.D.
President and Chief Medical Officer
VentiRx Pharmaceuticals, Inc.
(206) 689-2268
rhershberg@ventirx.com

Julie Rathbun

'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
4. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAKS, Calif. , July 24, 2014 Amgen ... report its second quarter financial results on Tuesday, July 29, ... announcement will be followed by a conference call with the ... from Amgen will be Robert A. Bradway , chairman ... management team. Live audio of the conference call ...
(Date:7/24/2014)... BUENA, N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE ... and manufacturing company, announced its financial results for the second ... Highlights , Total revenues of $6.5 million in ... the same quarter in 2013 , Total revenues of ... an increase of 78% over the same period in 2013 ...
(Date:7/24/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, today announced ... year 2014 financial results after the market close on ... follow on the same day at 4:30 p.m. ET. ... by Dan Myers , President and Chief Executive ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Second Quarter Financial Results 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2
(Date:7/25/2014)... Stwd.co.uk, one of the leading dress manufacturers ... cheap evening dress for women. In addition, the ... for these items. They are available at discounted rates, ... August 30. , “We are pleased to announce our ... have a large number of stylish special occasion gowns ...
(Date:7/25/2014)... July 25, 2014 Healthpointe is ... clinic is offering Occupational Medicine services to ... happily accepting referrals and workers’ compensation cases. ... Mirada clinic include wound care treatment management, return-to-work ... assessments, pre-employment screening & physicals, and illness and ...
(Date:7/25/2014)... MEDICC announced diplomas went to 1,382 new ... University of Havana’s graduation ceremonies that also included graduates ... the 879 international graduates from 28 countries, 20 were ... Professors and hundreds of parents packed the Cuban labor ... Vice President Ramón Machado Ventura and Minister of Health ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 CMS recently ... health plans for providing inadequate access to prescription drugs. ... to the health and safety of beneficiaries in areas ... coverage determinations, and CMS is taking quick and firm ... Atlantic Information Services webinar, “Avoiding Costly Part D ...
(Date:7/25/2014)... 2014 According to the ... by Vkool.com, this is a comprehensive guide ... some common types of hemorrhoids including:, ... ,     Young children with hemorrhoids , ...     Very large hemorrhoids and chronic hemorrhoids ...
Breaking Medicine News(10 mins):Health News:Famous Supplier Stwd.co.uk Announces Its New Selection of Evening Dresses for Women 2Health News:Healthpointe Offering Occupational Medicine Services in La Mirada 2Health News:MEDICC Congratulates 20 New MDs for the USA Graduating from Cuba’s Latin American Medical School 2Health News:MEDICC Congratulates 20 New MDs for the USA Graduating from Cuba’s Latin American Medical School 3Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 3
... Parents on How to Help Children Cope, WESTPORT, ... that responds to disasters and works to improve the,lives ... of crisis experts,to assist children and families affected by ... will be posted to San Diego, will provide assistance ...
... People with Diabetes Affected ... by California Wildfires, ALEXANDRIA, Va., ... for people with diabetes who,are affected by the California wildfires. ... supplies to manage their health. 1) Medication and Supplies -- ...
... of children with attention deficit hyperactivity disorder (ADHD) at ... was missing: the fathers., Fabiano, an assistant professor in the ... a graduate assistant at the UB Center for Children ... has helped more than 2,500 children with behavioral, emotional ...
... Fisher,Scientific Inc. (NYSE: TMO ), the world ... ground on a new $17 million (USD) facility ... services in that,country. The facility will focus on ... pharmaceutical samples to,patients participating in clinical trials across ...
... Md., Oct. 23 Martek Biosciences,Corporation (Nasdaq: ... of a,district court in Dusseldorf, Germany, has orally ... company,s patent infringement suit against (i) Lonza,Ltd., (ii) ... Food Ingredients GmbH. In a separate suit against ...
... BOTHELL, Wash., Oct. 23 Cardiac Science,Corporation (Nasdaq: ... cardiac monitoring,and defibrillation products, announced today that it ... Tuesday, October 30, 2007 after the,market close. The ... and,investors for 4:30 p.m. Eastern Time to discuss ...
Cached Medicine News:Health News:Save the Children to Help Youngsters Impacted by California Wildfires 2Health News:Save the Children to Help Youngsters Impacted by California Wildfires 3Health News:Save the Children to Help Youngsters Impacted by California Wildfires 4Health News:Save the Children to Help Youngsters Impacted by California Wildfires 5Health News:Emergency Preparedness for People With Diabetes 2Health News:Getting fathers involved in children's ADHD treatment programs 2Health News:Getting fathers involved in children's ADHD treatment programs 3Health News:Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 2Health News:Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 3Health News:Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with New Facility in India 4Health News:Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinova's Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements 2Health News:Martek Wins German DHA Patent Infringement Actions Against Lonza and One of Nutrinova's Customers in Suits Relating to DHA Product Marketed for Use in Functional Foods and Dietary Supplements 3Health News:Cardiac Science Corporation Schedules Third Quarter Earnings Release and Announces Conference Call 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: